Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408472 · ClinicalTrials.gov registry record · Phase 1
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
A Phase 1 study of Glaucoma, Primary Open Angle, sponsored by Jeffrey L Goldberg.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01408472: Completed Phase 1 study of Glaucoma, Primary Open Angle, sponsored by Jeffrey L Goldberg.
NCT01408472 is a Phase 1 study of Glaucoma, Primary Open Angle that has completed, run by Jeffrey L Goldberg. The registered enrollment target is 11 participants, below the 68-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01408472, a Phase 1 study of Glaucoma, Primary Open Angle, has completed, sponsored by Jeffrey L Goldberg.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple pre-clinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like glaucoma. We hypothesize that CNTF delivery to the human eye will provide neuroprotection (prevent loss of vision) and neuroenhancement (improve vision indices) in glaucoma. Patients in the trial will receive an NT-501 CNTF implant (made by Neurotech) into one eye, and will be carefully followed to evaluate safety and efficacy.
Primary Outcome
Safety will be evaluated by counting the number of patients with adverse events, including loss of vision, visual field, or retinal/optic nerve structure, and ocular complications such as pain and inflammation.
Conditions Studied
Interventions
- DRUG NT-501 CNTF Implant
Study Locations (1)
Florida
- Bascom Palmer Eye Institute, University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
What the finished NCT01408472 record still lists
NCT01408472 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 68-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Glaucoma, Primary Open Angle appearing as the primary indexed condition, and to 1 intervention - of which NT-501 CNTF Implant is the first listed.
NCT01408472 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01408472 about?
NCT01408472 is a clinical study titled "NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement". Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple pre-clinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like glaucoma. We hypothesize that CNTF delivery to the human eye will provide neuroprotection (prevent los...
What is the current status of trial NCT01408472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-04. Estimated completion is 2014-10.
What conditions does trial NCT01408472 study?
This clinical trial studies the following conditions: Glaucoma, Primary Open Angle.
What interventions are being tested in trial NCT01408472?
The interventions under investigation include: NT-501 CNTF Implant (DRUG).
Who is sponsoring clinical trial NCT01408472?
This trial is sponsored by Jeffrey L Goldberg, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01408472 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma, Primary Open Angle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and IOP-Lowering Effects of WB007
COMPLETED · Phase 1
-
Adaptive Optics Retinal Imaging
RECRUITING · NA
-
Safety and Feasibility of the ELIOS System in POAG Patients
RECRUITING · NA
-
Caffeine Consumption in Glaucoma Patients and Healthy Subjects
RECRUITING · NA
-
Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia